KKR invests $200m in India's Gland
This article was originally published in Scrip
Niche verticals such as injectables continue to attract private equity (PE) interest in India, with the global investment firm, KKR, acquiring a minority stake in Gland Pharma for about $200m – the largest PE investment in a local pharmaceutical firm in recent times.
You may also be interested in...
Shanghai Fosun Pharmaceutical Group Co. Ltd. has confirmed it interest in the Indian injectables firm, Gland Pharma Ltd., underscoring how differentiated niche plays continue to attract buyer interest.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.